ChinaDrugStatus

Covered Drugs

20 manually verified drugs linked to the 2026 China NRDL & Commercial List launch sample.

Download CSV (20 rows)
Showing 20 of 20 drugs
Generic / Chinese NameDosage FormChina Approval (NMPA)2026 Catalog StatusVerified
Mazdutide
玛仕度肽 · Xinermei / 信尔美
Endocrinology / Metabolic
Injection
Approved (Verified)
H20250036, H20250037, H20250038
NRDL 2026 Class B #30Announced · Effective Jan 1, 2027
2026-11-20
Relmacabtagene autoleucel
瑞基奥仑赛 · Carteyva / 倍诺达
Oncology / Cell Therapy
Injection (CAR-T)
Approved (Verified)
S20210035
NRDL 2026 Class B #297Announced · Effective Jan 1, 2027
2026-11-20
Insulin icodec / Semaglutide
依柯胰岛素司美格鲁肽 · Kyinsu / 诺和杰
Endocrinology / Metabolic
Injection
Approved (Verified)
SJ20260018
NRDL 2026 Class B #18Announced · Effective Jan 1, 2027
2026-11-20
Zolbetuximab
佐妥昔单抗 · Vyloy / 威络益
Oncology
Powder for Injection
Approved (Verified)
SJ20240050
NRDL 2026 Class B #287Announced · Effective Jan 1, 2027
2026-11-20
Datopotamab deruxtecan
德达博妥单抗 · Datroway / 达卓优
Oncology
Powder for Injection
Approved (Verified)
SJ20250021
NRDL 2026 Class B #288Announced · Effective Jan 1, 2027
2026-11-20
Sapropterin dihydrochloride
盐酸沙丙蝶呤 · 海普益
Rare Disease / Metabolic
Tablet
Approved (Verified)
H20233796
NRDL 2026 Class B #42Announced · Effective Jan 1, 2027
2026-11-20
Pamiparib
帕米帕利 · Partruvix / 百汇泽
Oncology
Capsule
Approved (Verified)
H20210016
NRDL 2026 RemovedAnnounced · Effective Jan 1, 2027
2026-11-20
Beraprost sodium (sustained-release)
贝前列素钠缓释片
Cardiovascular / Pulmonary
Sustained-Release TabletNMPA Pending Backfill
NRDL 2026 RemovedAnnounced · Effective Jan 1, 2027
2026-11-20
Xiao'er Niuhuang Qingxin San
小儿牛黄清心散
Traditional Chinese Medicine
Oral Powder (TCM)NMPA Pending Backfill
NRDL 2026 RemovedAnnounced · Effective Jan 1, 2027
2026-11-20
Shenlong Ningxin Capsules
参龙宁心胶囊
Traditional Chinese Medicine
Capsule (TCM)NMPA Pending Backfill
NRDL 2026 RemovedAnnounced · Effective Jan 1, 2027
2026-11-20
Dupilumab
度普利尤单抗 · Dupixent / 达必妥
Immunology / Dermatology
Injection
Approved (Verified)
SJ20200017
NRDL 2026 Class B #104Announced · Effective Jan 1, 2027
2026-11-20
Trastuzumab deruxtecan
德曲妥珠单抗 · Enhertu / 优赫得
Oncology
Powder for Injection
Approved (Verified)
SJ20230005
NRDL 2026 Class B #255Announced · Effective Jan 1, 2027
2026-11-20
Sacituzumab tirumotecan
芦康沙妥珠单抗 · 佳泰莱
Oncology
Powder for Injection
Approved (Verified)
S20240052
NRDL 2026 Class B #284Announced · Effective Jan 1, 2027
2026-11-20
Ivosidenib
艾伏尼布 · Tibsovo / 拓舒沃
Oncology / Hematology
Tablet
Approved (Verified)
HJ20220002
NRDL 2026 Class B #298Announced · Effective Jan 1, 2027
2026-11-20
Eliglustat tartrate
酒石酸艾格司他 · Cerdelga / 凯奇安
Rare Disease / Metabolic
CapsuleNMPA Pending Backfill
NRDL 2026 Class B #41Announced · Effective Jan 1, 2027
2026-11-20
Lutetium (177Lu) vipivotide tetraxetan
镥[177Lu]特昔维匹肽 · Pluvicto / 派威妥
Oncology / Radioligand
InjectionNMPA Pending Backfill
Commercial List #28Announced · Effective Jan 1, 2027
2026-11-20
Tofersen
托夫生 · Qalsody / 凯盛迪
Neurology / Rare Disease
Injection
Approved (Verified)
HJ20240102
Commercial List #25Announced · Effective Jan 1, 2027
2026-11-20
Eplontersen sodium
依普隆特生钠 · Wainua / 万诺维
Neurology / Rare Disease
Injection
Approved (Verified)
HJ20250151
Commercial List #24Announced · Effective Jan 1, 2027
2026-11-20
Inaticabtagene autoleucel
纳基奥仑赛 · 源瑞达
Oncology / Cell Therapy
Injection (CAR-T)
Approved (Verified)
S20230065
Commercial List #13Announced · Effective Jan 1, 2027
2026-11-20
Tazemetostat hydrobromide
氢溴酸他泽司他 · Tazverik / 达唯珂
Oncology / Hematology
Tablet
Approved (Verified)
HJ20250031
2025 Commercial List OnlyAnnounced · Effective Jan 1, 2027
2026-11-20